Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed at $13.48 down -1.53% from its previous closing price of $13.69. In other words, the price has decreased by -$1.53 from its previous closing price. On the day, 0.89 million shares were traded. AVDL stock price reached its highest trading level at $13.91 during the session, while it also had its lowest trading level at $13.4.
Ratios:
For a deeper understanding of Avadel Pharmaceuticals plc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 222.23. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.41.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $12.
On June 12, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $27.Rodman & Renshaw initiated its Buy rating on June 12, 2024, with a $27 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1308875648 and an Enterprise Value of 1265372160. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.92 while its Price-to-Book (P/B) ratio in mrq is 14.38. Its current Enterprise Value per Revenue stands at 5.724 whereas that against EBITDA is 3554.416.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.57, which has changed by -0.1627329 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $16.66, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 27.85%, while the 200-Day Moving Average is calculated to be 39.17%.
Shares Statistics:
For the past three months, AVDL has traded an average of 1.33M shares per day and 1533570 over the past ten days. A total of 96.78M shares are outstanding, with a floating share count of 88.92M. Insiders hold about 8.72% of the company’s shares, while institutions hold 80.88% stake in the company. Shares short for AVDL as of 1753920000 were 10855121 with a Short Ratio of 8.15, compared to 1751241600 on 12643707. Therefore, it implies a Short% of Shares Outstanding of 10855121 and a Short% of Float of 13.100000000000001.
Earnings Estimates
The stock of Avadel Pharmaceuticals plc (AVDL) is currently in the spotlight, with 5.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.12, with high estimates of $0.16 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.34 and $0.17 for the fiscal current year, implying an average EPS of $0.25. EPS for the following year is $0.85, with 5.0 analysts recommending between $1.21 and $0.49.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $73.71M this quarter.It ranges from a high estimate of $74.7M to a low estimate of $72.6M. As of the current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $50.02MFor the next quarter, 7 analysts are estimating revenue of $78.68M. There is a high estimate of $80.14M for the next quarter, whereas the lowest estimate is $77.1M.
A total of 7 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $274.9M, while the lowest revenue estimate was $270.4M, resulting in an average revenue estimate of $273.03M. In the same quarter a year ago, actual revenue was $169.12MBased on 8 analysts’ estimates, the company’s revenue will be $354.34M in the next fiscal year. The high estimate is $378.3M and the low estimate is $333.7M.
